CClinicalTrials.gg
Sign In
CompletedNCT04918108Updated Nov 20, 2024

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III

An observational study in Aortic Dissection, sponsored by Nanjing Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Nanjing Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. The authors evaluated the inflammatory response in patients with aortic dissection (AD) and assessed the presence of distinct inflammatory subphenotypes within this disease.

02

Conditions studied

  • Aortic Dissection

Browse trials for

Keywords

  • Aortic Dissection
  • Inflammatory Response
03

In context

Aortic Dissection

386 studies on the registry are indexed under Aortic Dissection; 117 are open to participants now.

This study's enrollment of 2,000 is above the median of 183 across 180 observational studies indexed under Aortic Dissection.

Browse Aortic Dissection studies →

Lead sponsor

Nanjing Medical University is the lead sponsor of 169 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients underwent venipuncture during primary evaluation in the Emergency Department. Venous blood samples were immediately sent to the laboratory for analysis.

Inclusion criteria

  • acute type Aortic dissection;

Exclusion criteria

Exclusion Criteria:

  • Iatrogenic aortic dissection OR traumatic aortic dissection
  • Patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases.
  • Preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (actual)
Patient registry
No

Groups and cohorts

  • inflammatory subphenotype

    Biological: inflammatory response

Interventions

  • Biologicalinflammatory response

    laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)

06

What researchers measure

Primary outcomes

  1. 30-day mortality

    any cause death within 30 days of surgery

    Time frame: 30 days after surgery

Secondary outcomes

  1. ICU mortality

    any cause death within ICU

    Time frame: 7 days after surgery

07

Study locations

1 site
  • The first affiliated hospital of nanjing medical university
    Nanjing, Jiangsu 210029, China
08

References and documents

Publications

  • Liu H, Qian SC, Han L, Dong ZQ, Shao YF, Li HY, Zhang W, Zhang HJ. Laboratory signatures differentiate the tolerance to hypothermic circulatory arrest in acute type A aortic dissection surgery. Interact Cardiovasc Thorac Surg. 2022 Nov 8;35(6):ivac267. doi: 10.1093/icvts/ivac267. PubMed 36271847 ↗
  • Liu H, Qian SC, Zhang YY, Wu Y, Hong L, Yang JN, Zhong JS, Wang YQ, Wu DK, Fan GL, Chen JQ, Zhang SQ, Peng XX, Shao YF, Li HY, Zhang HJ. A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy Score. Mayo Clin Proc Innov Qual Outcomes. 2022 Sep 25;6(6):497-510. doi: 10.1016/j.mayocpiqo.2022.08.005. eCollection 2022 Dec. Erratum In: Mayo Clin Proc Innov Qual Outcomes. 2024 Sep 16;8(5):481. doi: 10.1016/j.mayocpiqo.2024.08.002. PubMed 36185465 ↗
  • Liu H, Qian SC, Shao YF, Li HY; Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Investigators Group. Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection. J Inflamm Res. 2022 Jun 27;15:3709-3718. doi: 10.2147/JIR.S369703. eCollection 2022. PubMed 35783246 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04918108
Lead sponsor
Nanjing Medical University
Collaborators
The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Shantou University Medical College, The First Affiliated Hospital of Guangzhou Medical University, TEDA International Cardiovascular Hospital, Xiamen Cardiovascular Hospital, Shanghai East Hospital Tongji University, Tianjin Chest Hospital, Tianjin Medical University, Nanjing First Hospital, Nanjing Medical University, Xiangya Hospital of Central South University, The First Affiliated Hospital of Bengbu Medical University
Responsible party
Hong Liu (Investigator of Nanjing Medical University, Nanjing Medical University) — Principal investigator
First posted
Jun 8, 2021
Start date
Jan 1, 2021
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Last update
Nov 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Aortic Dissection→

Other studies from this sponsor

Nanjing Medical University

Start the discussion